Cargando…

Insights into CD47/SIRPα axis-targeting tumor immunotherapy

During the last decade, inhibitors targeting immune checkpoint programmed death ligand 1/PD-1 and cytotoxic T-lymphocyte-associated protein 4 have been one of the most significant advances for cancer therapy in clinic. However, most of these therapies focused on stimulating the adaptive immune syste...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xuyao, Fan, Jiajun, Ju, Dianwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157794/
https://www.ncbi.nlm.nih.gov/pubmed/34056543
http://dx.doi.org/10.1093/abt/tby006